CDK4/6 inhibition radiosensitizes p16-negative squamous cell carcinomas of the aerodigestive tract via cell cycle arrest.

Meghan Lambie^1,2, Aakshi Puri^1,2, Rita Gill¹, Ariana Rostami^1,2, Maria Kondratyev¹, Bradly G Wouters^1,2,3, Laurie Ailles^1,2, Benjamin Haibe-Kains^1,2,4,5,6, Scott V Bratman^1,2,3

¹Princess Margaret Cancer Center, University Health Network, Toronto, ON, Canada.

²Department of Medical Biophysics, University of Toronto, Toronto, ON, Canada.

³Department of Radiation Oncology, University of Toronto, Toronto, ON, Canada.

⁴Department of Computer Science, University of Toronto, Toronto, ON, Canada.

⁵Structural Genomics Consortium, Toronto, ON, Canada.

⁶Vector Institute for Artificial Intelligence, Toronto, ON, Canada.

PubMed DOI

Abstract

INTRODUCTION: CDK4/6 inhibitors have quickly entered clinical guidelines for luminal breast cancer, but their role in other cancer types remains to be defined. Squamous cell carcinomas not driven by human papillomavirus (HPV-negative SCCs) are frequently treated with radiotherapy, and concurrent treatment with CDK4/6 inhibitors has been proposed. We sought to investigate the efficacy of this combi…

Create a free account to keep reading

Free members get 10 full research views every month across publications, clinical trials, FDA clearances, adverse events, and NIH grants. No credit card required.

Create Free Account Sign In

Want unlimited research access? See Pro plans

Data Accuracy Notice: Research intelligence on Health AI Central is aggregated from public sources (PubMed, ClinicalTrials.gov, FDA, NIH, CMS, and others) and refreshed nightly. Classifications and derived metrics are produced by automated methods described in our Methodology. We recommend verifying critical data points against the primary sources before making decisions.